TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Evaxion expands AI-Immunology™ platform into autoimmune diseases

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Evaxion expands AI-Immunology™ platform into autoimmune diseases

Evaxion A/S announced expansion of its AI-Immunology platform to include autoimmune diseases as a third disease area alongside cancer and infectious diseases. The company outlined 2026 milestones including biomarker data for EVX-01, autoimmune disease application development, three-year phase 2 efficacy data, and regulatory filings. Cash runway extends to second half of 2027. Additionally, MSD declined to exercise its option on the Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to out-license it to other partners.

Insights
VOO   neutral

Mentioned as top holding in Financial Sense Advisors' portfolio without specific performance commentary


EVAX   positive

Company is strategically expanding its platform into a new high-value disease area (autoimmune diseases) with significant partnership potential, maintaining strong cash runway into H2 2027, and achieving multiple clinical and regulatory milestones in 2026. The expansion leverages existing technology without impacting cash position, demonstrating efficient capital allocation and business growth.